310 related articles for article (PubMed ID: 26202864)
1. Assessment of minimal residual disease in myeloma and the need for a consensus approach.
Rawstron AC; Paiva B; Stetler-Stevenson M
Cytometry B Clin Cytom; 2016 Jan; 90(1):21-5. PubMed ID: 26202864
[TBL] [Abstract][Full Text] [Related]
2. Measuring disease levels in myeloma using flow cytometry in combination with other laboratory techniques: Lessons from the past 20 years at the Leeds Haematological Malignancy Diagnostic Service.
Rawstron AC; de Tute RM; Haughton J; Owen RG
Cytometry B Clin Cytom; 2016 Jan; 90(1):54-60. PubMed ID: 26147493
[TBL] [Abstract][Full Text] [Related]
3. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma.
Flores-Montero J; de Tute R; Paiva B; Perez JJ; Böttcher S; Wind H; Sanoja L; Puig N; Lecrevisse Q; Vidriales MB; van Dongen JJ; Orfao A
Cytometry B Clin Cytom; 2016 Jan; 90(1):61-72. PubMed ID: 26100534
[TBL] [Abstract][Full Text] [Related]
4. Better therapy requires better response evaluation: Paving the way for minimal residual disease testing for every myeloma patient.
Landgren O; Owen RG
Cytometry B Clin Cytom; 2016 Jan; 90(1):14-20. PubMed ID: 26147584
[TBL] [Abstract][Full Text] [Related]
5. Flow cytometry quality requirements for monitoring of minimal disease in plasma cell myeloma.
Oldaker TA; Wallace PK; Barnett D
Cytometry B Clin Cytom; 2016 Jan; 90(1):40-6. PubMed ID: 26201282
[TBL] [Abstract][Full Text] [Related]
6. Regulatory perspective on minimal residual disease flow cytometry testing in multiple myeloma.
Gormley NJ; Turley DM; Dickey JS; Farrell AT; Reaman GH; Stafford E; Carrington L; Marti GE
Cytometry B Clin Cytom; 2016 Jan; 90(1):73-80. PubMed ID: 26108351
[TBL] [Abstract][Full Text] [Related]
7. Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting.
Arroz M; Came N; Lin P; Chen W; Yuan C; Lagoo A; Monreal M; de Tute R; Vergilio JA; Rawstron AC; Paiva B
Cytometry B Clin Cytom; 2016 Jan; 90(1):31-9. PubMed ID: 25619868
[TBL] [Abstract][Full Text] [Related]
8. Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition.
Stetler-Stevenson M; Paiva B; Stoolman L; Lin P; Jorgensen JL; Orfao A; Van Dongen J; Rawstron AC
Cytometry B Clin Cytom; 2016 Jan; 90(1):26-30. PubMed ID: 25907102
[TBL] [Abstract][Full Text] [Related]
9. Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimen.
de Tute RM; Rawstron AC; Gregory WM; Child JA; Davies FE; Bell SE; Cook G; Szubert AJ; Drayson MT; Jackson GH; Morgan GJ; Owen RG
Haematologica; 2016 Feb; 101(2):e69-71. PubMed ID: 26471484
[No Abstract] [Full Text] [Related]
10. The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma.
Paiva B; Chandia M; Puig N; Vidriales MB; Perez JJ; Lopez-Corral L; Ocio EM; Garcia-Sanz R; Gutierrez NC; Jimenez-Ubieto A; Lahuerta JJ; Mateos MV; San Miguel JF
Haematologica; 2015 Feb; 100(2):e53-5. PubMed ID: 25381128
[No Abstract] [Full Text] [Related]
11. Utility and feasibility of a six-color multiparametric flow cytometry for measurable residual disease analysis in plasma cell myeloma in resource-limited settings with 5-year survival data.
Sharma P; Singh Sachdeva MU; Varma N; Bose P; Aggarwal R; Malhotra P
J Cancer Res Ther; 2021; 17(6):1515-1520. PubMed ID: 34916387
[TBL] [Abstract][Full Text] [Related]
12. Molecular monitoring of minimal residual disease in the peripheral blood of patients with multiple myeloma.
Korthals M; Sehnke N; Kronenwett R; Schroeder T; Strapatsas T; Kobbe G; Haas R; Fenk R
Biol Blood Marrow Transplant; 2013 Jul; 19(7):1109-15. PubMed ID: 23644045
[TBL] [Abstract][Full Text] [Related]
13. Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation.
Rawstron AC; Davies FE; DasGupta R; Ashcroft AJ; Patmore R; Drayson MT; Owen RG; Jack AS; Child JA; Morgan GJ
Blood; 2002 Nov; 100(9):3095-100. PubMed ID: 12384404
[TBL] [Abstract][Full Text] [Related]
14. Assessment of response to therapy in multiple myeloma by multiparameter flow cytometry. Usefulness of an eight-color single tube with monoclonal antibodies in dried formulation.
Carulli G; Tarasco A; Sammuri P; Ottaviano V; Domenichini C; Ciancia EM; Petrini M
Clin Ter; 2019; 170(5):e352-e356. PubMed ID: 31612192
[TBL] [Abstract][Full Text] [Related]
15. Minimal residual disease and log-reduction of plasma cells are associated with superior response after double autologous stem cell transplant in younger patients with multiple myeloma.
Rossi G; Falcone AP; Minervini MM; De Cillis GP; De Waure C; Sisti LG; Giambra V; Valente D; Chiello V; Scalzulli PR; Carella AM; Cascavilla N
Cytometry B Clin Cytom; 2019 May; 96(3):195-200. PubMed ID: 30549231
[TBL] [Abstract][Full Text] [Related]
16. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study.
Rawstron AC; Child JA; de Tute RM; Davies FE; Gregory WM; Bell SE; Szubert AJ; Navarro-Coy N; Drayson MT; Feyler S; Ross FM; Cook G; Jackson GH; Morgan GJ; Owen RG
J Clin Oncol; 2013 Jul; 31(20):2540-7. PubMed ID: 23733781
[TBL] [Abstract][Full Text] [Related]
17. Introduction to multiple myeloma special issue: The flow cytometric detection of minimal residual disease.
Preffer FI; Yuan CM; Lin P; Stetler-Stevenson M; Marti GE
Cytometry B Clin Cytom; 2016 Jan; 90(1):9-10. PubMed ID: 26780351
[No Abstract] [Full Text] [Related]
18. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma.
Lemoli RM; Cavo M; Fortuna A
J Hematother; 1996 Aug; 5(4):339-49. PubMed ID: 8877709
[TBL] [Abstract][Full Text] [Related]
19. Minimal residual disease detection in multiple myeloma: comparison between BML single-tube 10-color multiparameter flow cytometry and EuroFlow multiparameter flow cytometry.
Sato K; Okazuka K; Ishida T; Sakamoto J; Kaneko S; Nashimoto J; Uto Y; Ogura M; Yoshiki Y; Abe Y; Maeda A; Hamazaki H; Tsukada N; Hiragohri Y; Suzuki K
Ann Hematol; 2021 Dec; 100(12):2989-2995. PubMed ID: 34430990
[TBL] [Abstract][Full Text] [Related]
20. Validation of a modified pre-lysis sample preparation technique for flow cytometric minimal residual disease assessment in multiple myeloma, chronic lymphocytic leukemia, and B-non Hodgkin lymphoma.
Bayly E; Nguyen V; Binek A; Piggin A; Baldwin K; Westerman D; Came N
Cytometry B Clin Cytom; 2020 Sep; 98(5):385-398. PubMed ID: 32530574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]